DAWN Q2 2024 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$7M91.4% margin

Operating Income

-$115M-1401.5% margin

Net Income

-$4M-53.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$66M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$400M

Total Liabilities

$94M

Stockholders' Equity

$307M

Cash & Equivalents

$240M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$7M	-$92,000	+8235.9%
Operating Income	-$115M	-$49M	-133.1%
Net Income	-$4M	-$46M	+90.4%

Revenue Segments

Product

$8M100%